Association between adjuvant therapy and survival in colorectal cancer patients according to metabolic Warburg-subtypes.
Kelly OffermansJosien C A JenniskensColinda C J M SimonsIryna V SamarskaGregorio E FazziKim M SmitsLeo J SchoutenMatty P WeijenbergHeike I GrabschPiet A van den BrandtPublished in: Journal of cancer research and clinical oncology (2023)
Our results suggest that Warburg-subtypes may predict survival benefit from adjuvant therapy in CRC patients. A survival benefit from adjuvant therapy was observed for patients with Warburg-moderate and possibly Warburg-high CRC, but not for patients with Warburg-low CRC. Future prospective studies are necessary to validate our findings.